Cargando…
Induction Chemotherapy Followed by Primary Tumor Resection Did Not Bring Survival Benefits in Colon Cancer Patients With Asymptomatic Primary Lesion and Synchronous Unresectable Metastases
BACKGROUND: It is still controversial whether primary tumor resection (PTR) improves survival in colorectal cancer (CRC) patients with unresectable metastases. METHODS: Colon cancer patients were enrolled and randomly allocated to with or without PTR after induction chemotherapy with XELOX or mFOLFO...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841852/ https://www.ncbi.nlm.nih.gov/pubmed/35174078 http://dx.doi.org/10.3389/fonc.2022.747124 |
_version_ | 1784650932866252800 |
---|---|
author | Huang, Mingzhu Yang, Ya’nan Li, Qingguo Wang, Chenchen Liang, Lei Zhu, Xiaodong Zhang, Wen Chen, Zhiyu Huang, Dan Li, Wenhua Zhang, Xiaowei Zhao, Xiaoying Qiu, Lixin Geng, Qirong Yu, Nuoya Du, Wenfang Sun, Sijie Sheng, Xuedan Li, Xinxiang Guo, Weijian |
author_facet | Huang, Mingzhu Yang, Ya’nan Li, Qingguo Wang, Chenchen Liang, Lei Zhu, Xiaodong Zhang, Wen Chen, Zhiyu Huang, Dan Li, Wenhua Zhang, Xiaowei Zhao, Xiaoying Qiu, Lixin Geng, Qirong Yu, Nuoya Du, Wenfang Sun, Sijie Sheng, Xuedan Li, Xinxiang Guo, Weijian |
author_sort | Huang, Mingzhu |
collection | PubMed |
description | BACKGROUND: It is still controversial whether primary tumor resection (PTR) improves survival in colorectal cancer (CRC) patients with unresectable metastases. METHODS: Colon cancer patients were enrolled and randomly allocated to with or without PTR after induction chemotherapy with XELOX or mFOLFOX6, and those with chemotherapy failure were excluded. The primary endpoint was TTF (time to strategy failure) on an intent-to-treat basis. This study is registered with ClinicalTrials.gov, number NCT02291744. RESULTS: Between April 2015 and July 2020, 140 patients were enrolled, and 54 patients were excluded due to colon obstruction (16), perforation (1), disease progression (22), death (1), radical resection (3), or other reasons (11). After induction chemotherapy, 86 patients were randomized into group A (the resection group, n = 42) or group B (chemotherapy-alone group, n = 44). The median TTF was 143 days (95% CI: 104.9–181.1) in group A and 196 days (95% CI: 96.5–295.5) in group B (HR: 0.930 95% CI: 0.589–1.468, p = 0.755), and there was no significant difference in PFS, OS, and incidence of chemotherapy-related adverse events between two groups. The primary lesion-related events after PTR in group A were significantly fewer than those in group B. Patients with a tumor regression grade (TRG) score of 2 had longer TTF and PFS than those with score of 3. CONCLUSION: PTR after induction chemotherapy could not bring survival benefits for colon cancer patients with unresectable metastases, and it is not recommended routinely. However, it also requires individualized treatment as colon obstruction or perforation occurred in some patients and PTR could reduce primary tumor-related events, and the TRG score might help for selection of beneficial patients. |
format | Online Article Text |
id | pubmed-8841852 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88418522022-02-15 Induction Chemotherapy Followed by Primary Tumor Resection Did Not Bring Survival Benefits in Colon Cancer Patients With Asymptomatic Primary Lesion and Synchronous Unresectable Metastases Huang, Mingzhu Yang, Ya’nan Li, Qingguo Wang, Chenchen Liang, Lei Zhu, Xiaodong Zhang, Wen Chen, Zhiyu Huang, Dan Li, Wenhua Zhang, Xiaowei Zhao, Xiaoying Qiu, Lixin Geng, Qirong Yu, Nuoya Du, Wenfang Sun, Sijie Sheng, Xuedan Li, Xinxiang Guo, Weijian Front Oncol Oncology BACKGROUND: It is still controversial whether primary tumor resection (PTR) improves survival in colorectal cancer (CRC) patients with unresectable metastases. METHODS: Colon cancer patients were enrolled and randomly allocated to with or without PTR after induction chemotherapy with XELOX or mFOLFOX6, and those with chemotherapy failure were excluded. The primary endpoint was TTF (time to strategy failure) on an intent-to-treat basis. This study is registered with ClinicalTrials.gov, number NCT02291744. RESULTS: Between April 2015 and July 2020, 140 patients were enrolled, and 54 patients were excluded due to colon obstruction (16), perforation (1), disease progression (22), death (1), radical resection (3), or other reasons (11). After induction chemotherapy, 86 patients were randomized into group A (the resection group, n = 42) or group B (chemotherapy-alone group, n = 44). The median TTF was 143 days (95% CI: 104.9–181.1) in group A and 196 days (95% CI: 96.5–295.5) in group B (HR: 0.930 95% CI: 0.589–1.468, p = 0.755), and there was no significant difference in PFS, OS, and incidence of chemotherapy-related adverse events between two groups. The primary lesion-related events after PTR in group A were significantly fewer than those in group B. Patients with a tumor regression grade (TRG) score of 2 had longer TTF and PFS than those with score of 3. CONCLUSION: PTR after induction chemotherapy could not bring survival benefits for colon cancer patients with unresectable metastases, and it is not recommended routinely. However, it also requires individualized treatment as colon obstruction or perforation occurred in some patients and PTR could reduce primary tumor-related events, and the TRG score might help for selection of beneficial patients. Frontiers Media S.A. 2022-01-31 /pmc/articles/PMC8841852/ /pubmed/35174078 http://dx.doi.org/10.3389/fonc.2022.747124 Text en Copyright © 2022 Huang, Yang, Li, Wang, Liang, Zhu, Zhang, Chen, Huang, Li, Zhang, Zhao, Qiu, Geng, Yu, Du, Sun, Sheng, Li and Guo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Huang, Mingzhu Yang, Ya’nan Li, Qingguo Wang, Chenchen Liang, Lei Zhu, Xiaodong Zhang, Wen Chen, Zhiyu Huang, Dan Li, Wenhua Zhang, Xiaowei Zhao, Xiaoying Qiu, Lixin Geng, Qirong Yu, Nuoya Du, Wenfang Sun, Sijie Sheng, Xuedan Li, Xinxiang Guo, Weijian Induction Chemotherapy Followed by Primary Tumor Resection Did Not Bring Survival Benefits in Colon Cancer Patients With Asymptomatic Primary Lesion and Synchronous Unresectable Metastases |
title | Induction Chemotherapy Followed by Primary Tumor Resection Did Not Bring Survival Benefits in Colon Cancer Patients With Asymptomatic Primary Lesion and Synchronous Unresectable Metastases |
title_full | Induction Chemotherapy Followed by Primary Tumor Resection Did Not Bring Survival Benefits in Colon Cancer Patients With Asymptomatic Primary Lesion and Synchronous Unresectable Metastases |
title_fullStr | Induction Chemotherapy Followed by Primary Tumor Resection Did Not Bring Survival Benefits in Colon Cancer Patients With Asymptomatic Primary Lesion and Synchronous Unresectable Metastases |
title_full_unstemmed | Induction Chemotherapy Followed by Primary Tumor Resection Did Not Bring Survival Benefits in Colon Cancer Patients With Asymptomatic Primary Lesion and Synchronous Unresectable Metastases |
title_short | Induction Chemotherapy Followed by Primary Tumor Resection Did Not Bring Survival Benefits in Colon Cancer Patients With Asymptomatic Primary Lesion and Synchronous Unresectable Metastases |
title_sort | induction chemotherapy followed by primary tumor resection did not bring survival benefits in colon cancer patients with asymptomatic primary lesion and synchronous unresectable metastases |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841852/ https://www.ncbi.nlm.nih.gov/pubmed/35174078 http://dx.doi.org/10.3389/fonc.2022.747124 |
work_keys_str_mv | AT huangmingzhu inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT yangyanan inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT liqingguo inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT wangchenchen inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT lianglei inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT zhuxiaodong inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT zhangwen inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT chenzhiyu inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT huangdan inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT liwenhua inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT zhangxiaowei inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT zhaoxiaoying inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT qiulixin inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT gengqirong inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT yunuoya inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT duwenfang inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT sunsijie inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT shengxuedan inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT lixinxiang inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases AT guoweijian inductionchemotherapyfollowedbyprimarytumorresectiondidnotbringsurvivalbenefitsincoloncancerpatientswithasymptomaticprimarylesionandsynchronousunresectablemetastases |